| WHO
grade III and IV systemic side effects after TNF-based ILP.
| Reference |
Year |
Treatment
Combinationa |
No.
of
Patients |
Side
Effect Observed (%) |
| Hypotension |
Lung |
Kidney |
Liver |
Blood |
| 56 |
1994 |
TIM |
53 |
1.7 |
17 |
1.7 |
12 |
7 |
| 57 |
1996 |
TIM |
26 |
39 |
8 |
0 |
27 |
8 |
| 70 |
1996 |
TIM |
59 |
1.6 |
1.6 |
1.6 |
12 |
7 |
| 61b |
1999 |
TIM |
32 |
9 |
3 |
0 |
0 |
0 |
| 61b |
1999 |
TM |
32 |
16 |
9 |
0 |
0 |
0 |
aAbbreviations:
TIM, TNF/IFN-γ/melphalan; TM, TNF/melphalan.
bRandomised phase II study in melanoma where a comparison of TIM
with TM was made.
|
